Mutual Launches Malaria Drug Qualaquin, Warns Of Unapproved Competitors
This article was originally published in The Pink Sheet Daily
Executive Summary
Company hopes to get FDA to remove other quinine products from the market.
You may also be interested in...
FDA Takes Unapproved Quinine Drugs Off The Market
Physicians warned against prescribing for leg cramps, which accounts for 70% of usage.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.